<DOC>
	<DOCNO>NCT01163071</DOCNO>
	<brief_summary>The purpose study determine MTD and/or RP2D ABI-011 administer IV Day 1 , Day 8 Day 15 one week rest patient advance solid tumor malignancy lymphomas .</brief_summary>
	<brief_title>A Phase 1 Trial ABI-011 Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>Dose limit toxicity ( DLT ) , maximum tolerate dose ( MTD )</detailed_description>
	<criteria>Must equal great 18 year age ECOG performance status less equal 2 ( Appendix 2 ) Pts . must willing able sign inform consent Cytologically histologically confirm solid tumor malignancy lymphoma standard approve therapy available . Patients accessible tumor lesion amendable 2 serial biopsy would put patient treatment risk Pt . agree willing provide 2 serial tumor biopsy ( optional first phase , mandatory 2nd phase ) During dose escalation phase , measurable nonmeasurable disease define RECIST criterion . At 2nd phase , patient measurable disease Life expectancy equal great 12 week All AEs prior chemotherapy , surgery radiotherapy , must resolve grade equal le 1 The following laboratory result must present within 14 day initial ABI011 administration Hemoglobin great equal 9g/dL Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L Platelet count great equal 100 x 10^9/L Serum bilirubin less equal 1.5 x upper limit normal ( ULN ) Aspartate transaminase ( AST ) alanine transaminase ( ALT ) less equal 2.5 ULN ( except liver metastasis present ; value must less equal 5 x ULN ) Potassium , correct calcium magnesium WNL Serum Creatinine less equal 1.5 x ULN Activated aPTT , PT , INR , WNL WNL level : Troponin I T , CKMB , BNP At least one measurable lesion evaluable ( DCEMRI eligibility criterion ) meet least one criterion : At least one measurable lesion least 3 cm diameter near diaphragm mediastinum Lesions solid mass enhance contrast , without sign calcification recent compute tomography ( CT ) magnetic resonance ( MRI ) scan Pts . must willing practice contraceptive method duration study one month follow study completion . Female patient must postmenopausal , surgically sterile must agree use acceptable method birth control . Male patient must surgically sterile agree use acceptable method contraception . Women childbearing potential must negative serum pregnancy test ( BhCG ) within 72 hour prior first study drug administration Inability comply study followup procedure Women pregnant lactating Treatment chemotherapy , hormonal therapy ( except leuprolide prostate cancer ) , immunotherapy , biologic therapy , radiation therapy cancer therapy within 4 week initiation study treatment . Six week elapse prior chemotherapy treatment include nitrosoureas mitomycin C Pts . receive antibodybased therapy within 28 day 5 halflives agent , whichever time period longer Major surgery within 6 week first study drug administration Prior treatment tumor vascular disruptive agent Any uncontrolled medical psychiatric risk factor Central nervous system ( CNS ) metastases . History diabetic retinopathy . All patient must evaluate ophthalmologist prior study treatment Any history myopathy , either peripheral cardiac Current use medication may potential QTc prolongation History allergy hypersensitivity compound ABI011 formulation Active uncontrolled bacterial , viral , fungal infection , require systemic therapy Pt.has know infection human immunodeficiency virus ( HIV ) , know chronic Hepatitis B Hepatitis C Inability venipunctured and/or tolerate venous access History carcinoma within past 5 year Pts . require therapeutic anticoagulation either coumadin low molecular weight heparin history bleed diathesis . Low dose aspirin low dose coumadin catheter maintenance allow Lung tumor central position . Cardiac exclusion criterion : Left ventricular ejection fraction ( LVEF ) &lt; 50 % echocardiography ; Previous history MI ischemic heart disease EKG finding suggestive current previous ischemic heart disease , include leave bundle branch block Prior treatment chemotherapy agent know potentially cause cardiotoxicity Class III IV heart failure define New York Heart ( NYHA ) functional classification Congenital acquire long QT syndrome Uncontrolled hypertension Current past history clinically significant arrhythmias QTc prolongation HO Symptomatic PVD ( Venous arterial ) Seizure disease require current anticonvulsant treatment HO previous CVA TIA HO inflammatory bowel disease ( active past ) active PUD HO previous , whole abdomen radiation therapy Grade 1 residual toxicity previous radiation therapy . History autoimmune disease vascular disease ( venous arterial )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>